Company intelligence / Profile preview

盛世泰科

Suzhou, Jiangsu, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

HighThink Pharmaceutical is a biopharmaceutical company headquartered in Suzhou, China, dedicated to the development of innovative small molecule therapeutics. The company focuses primarily on metabolic diseases and oncology, leveraging its proprietary drug discovery platform to create best-in-class and first-in-class medicines. Its lead product, Shengliptin, is a DPP-4 inhibitor that has received marketing approval in China for the treatment of type 2 diabetes. HighThink's pipeline includes several clinical-stage candidates targeting FGFR and ALK/ROS1/TRK for various cancer indications. The company aims to address significant unmet medical needs by providing high-quality and accessible treatment options for patients globally.

Therapeutic areas: EndocrinologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 盛世泰科.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 盛世泰科.

Explore the full profile